Piramal Pharma, a leading global pharmaceutical company, has announced the expansion of its biologics manufacturing infrastructure to enhance its drug development capabilities. This strategic move is aimed at strengthening the company’s position in the biopharmaceutical market and providing innovative solutions to patients worldwide.

The expansion includes the addition of new biologics manufacturing facilities, which will increase the company’s production capacity and enable it to cater to the growing demand for biologics. The new facilities will be equipped with state-of-the-art technology and will adhere to the highest standards of quality and regulatory compliance. The company has invested significantly in the expansion, demonstrating its commitment to delivering high-quality biologics to patients.

Piramal Pharma’s biologics manufacturing infrastructure will provide a comprehensive range of services, including cell line development, process development, and commercial manufacturing. The company’s expertise in biologics manufacturing will enable it to support clients across various stages of drug development, from early-stage research to commercial production.

The expansion of Piramal Pharma’s biologics manufacturing infrastructure is expected to have a positive impact on the pharmaceutical industry. It will provide access to high-quality biologics manufacturing services, enabling pharmaceutical companies to bring new treatments to market more quickly and efficiently. This, in turn, will benefit patients worldwide, who will have access to innovative and life-changing therapies.

The company’s investment in biologics manufacturing is also a testament to the growing importance of biologics in the pharmaceutical industry. Biologics have revolutionized the treatment of various diseases, including cancer, autoimmune disorders, and rare genetic disorders. As the demand for biologics continues to grow, Piramal Pharma is well-positioned to support the development and manufacturing of these complex therapies.

In conclusion, Piramal Pharma’s expansion of its biologics manufacturing infrastructure is a significant development in the pharmaceutical industry. The company’s commitment to delivering high-quality biologics manufacturing services will enable pharmaceutical companies to bring new treatments to market, ultimately benefiting patients worldwide. With its state-of-the-art facilities and expertise in biologics manufacturing, Piramal Pharma is poised to play a leading role in the development and manufacturing of biologics, shaping the future of the pharmaceutical industry.

Overall, Piramal Pharma’s investment in biologics manufacturing infrastructure reflects the company’s dedication to innovation, quality, and patient-centricity. As the pharmaceutical industry continues to evolve, Piramal Pharma is well-positioned to address the growing demand for biologics and make a meaningful impact on the lives of patients worldwide.

Piramal Consumer Healthcare has launched a new campaign for its i-pill Daily product, which aims to promote women’s health, dignity, and informed choice. The campaign highlights the importance of choosing the right brand, especially in a category where substitution is common and purchases are often made with hesitation. The goal is to encourage consumers to ask boldly, insist clearly, and choose confidently, rather than settling for a substitute due to discomfort or haste.

The campaign is set in a black-and-white style and aims to tackle the barrier of lack of insistence on the right brand at the moment of purchase. The film cleverly draws attention to the outdated discomfort surrounding the buying experience and flips the narrative by urging viewers to ask questions, assert their agency, and choose a trusted brand like i-pill Daily.

According to Nandini Piramal, Chairperson of Piramal Pharma Limited, every woman deserves access to healthcare that is safe, reliable, and respectful of her choices. The campaign reminds women that their health is too important to be left to chance or compromise and encourages them to choose what’s best for them.

Menaka Menon, President and Managing Partner of DDB Mudra Group, commented that the campaign aims to tackle the problem of consumers ending up with a substitute product due to social conditioning and embarrassment around the purchase of a contraceptive product. The campaign plays up the shift in society towards women exercising their discretion and choice, and contrasts it with the meek acceptance typically associated with such decisions in the past.

The campaign is backed by Piramal Pharma’s strong record in women’s wellness and is recognized as one of India’s Most Trusted Brands by Marksmen. It marks a strategic shift from generic awareness to informed, quality-first decisions. The film will be supported across digital platforms, including YouTube and Instagram, and will be amplified on television in select priority markets.

Overall, the campaign aims to empower women to make informed choices about their reproductive health and to choose a trusted brand like i-pill Daily. By encouraging consumers to ask boldly and insist clearly, the campaign hopes to reverse the trend of substitution and promote a culture of confidence and assertiveness around women’s health.

Piramal Consumer Healthcare has launched a new campaign for its emergency contraceptive pill, i-pill Daily, with the aim of empowering women to take control of their reproductive health and make informed choices. The campaign highlights the importance of insisting on the right brand at the point of purchase, as many women often end up with a substitute due to discomfort and haste during the buying experience. The campaign encourages women to “ask boldly, insist clearly, and choose confidently” when it comes to their reproductive health.

The film, shot in black and white, tackles the outdated discomfort surrounding the purchase of contraceptive products and urges viewers to assert their agency and choose a trusted brand like i-pill Daily. The campaign is built on the idea that every woman deserves access to healthcare that is safe, reliable, and respectful of her choices. Nandini Piramal, Chairperson of Piramal Pharma Limited, stated that the campaign is a reminder to women that their health is too important to be left to chance or compromise.

The campaign aims to address the issue of substitution, where women often end up with a different brand due to social conditioning and embarrassment. Menaka Menon, President and Managing Partner of DDB Mudra Group, commented that the campaign plays on the shift in society towards women exercising their discretion and choice, and contrasts it with the meek acceptance typically associated with such decisions in the past.

The film will be supported across digital platforms, including YouTube and Instagram, and will be amplified on television in select priority markets. The campaign is a significant step towards promoting women’s health, dignity, and informed choice, and encouraging women to take control of their reproductive health. By emphasizing the importance of choosing a trusted brand like i-pill Daily, the campaign aims to convert salience into sales at the point of purchase and promote a more empowered and informed approach to women’s healthcare.

The pharmaceutical industry is experiencing a period of uncertainty due to recent US policy directives, which are causing global pharmaceutical companies to delay major outsourcing decisions. Piramal Pharma, a contract development and manufacturing organization (CDMO), is taking a cautious approach and waiting for clarity on US policy before making any major commitments. Despite this, the company remains optimistic about its future prospects due to its geographically diverse network, which spans the US, UK, and India.

Piramal Pharma’s chairperson, Nandini Piramal, stated that decision-making has been prolonged, with clients holding off on commitments until there is more certainty. However, the company has seen an increase in requests for proposals (RFPs) and is confident that its network will position it well once the landscape stabilizes. The company anticipates muted growth in the short term, but expects a strong rebound by FY27 as the environment stabilizes and client commitments resume.

In FY25, Piramal Pharma reported a robust performance, with revenue increasing by 12% to ₹9,151 crore. The CDMO business contributed significantly, with revenue increasing by 15% year-on-year. The company also reported a 17% EBITDA margin and a fivefold increase in net profits. Looking ahead, Piramal Pharma is investing $90 million to expand two of its manufacturing facilities in the US, which aligns with its long-term goal of becoming a $2 billion revenue company by FY2030.

The US policy directives, introduced under President Donald Trump’s administration, have created a ripple of hesitation across the pharmaceutical sector. The directives call for domestic drug manufacturing and global price alignment for branded drugs, which has made it harder for CDMOs to secure new business from global pharma clients. However, Piramal Pharma is well-positioned to navigate this uncertainty due to its diverse network and strategic investments in the US. With a strong track record of performance and a clear roadmap for growth, Piramal Pharma is confident that it will emerge stronger once the industry uncertainty subsides.